To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Tuesday, January 14, 2020
The FDA last week approved Merck & Co.'s Keytruda for...
...non-muscle-invasive bladder
cancer, a rare form of the disease that does not respond well to other
treatments. Keytruda is the first new approval in the space in more than 20
years. For the treatment of urothelial carcinoma, the most common form of
bladder cancer, Keytruda is currently one of the most advantaged therapies on
the market, holding preferred status for 10% of all covered lives in the
pharmacy benefit, growing to 14% with prior authorization and/or step therapy.
SOURCE: MMIT Analytics, as
of 1/10/20
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment